miR-221 Mediates Chemoresistance of Esophageal Adenocarcinoma by Direct Targeting of DKK2 Expression by Wang, Yan et al.
ESA PAPERmiR-221 Mediates Chemoresistance of Esophageal
argeting of DKK2 ExpressionAdenocarcinoma by Direct TYan Wang, PhD, Yue Zhao, PhD, Andreas Herbst, PhD,z Thomas Kalinski, MD,§ Jiwei Qin, MS,
Xiaoyan Wang, MS, Zhenzhong Jiang, MD, Frank Benedix, MD,y Sabine Franke, PhD,§
Thomas Wartman, PhD,y Peter Camaj, PhD, Walter Halangk, PhD,y Frank T. Kolligs, MD,z
Karl W. Jauch, MD, Peter J. Nelson, PhD,jj and Christiane J. Bruns, MDBackground: Chemoresistance is a main obstacle to effective esophageal
cancer (EC) therapy. We hypothesize that altered expression of microRNAs
(miRNAs) play a role in EC cancer progression and resistance to 5-fluorour-
acil (5-FU) based chemotherapeutic strategies.
Methods: Four pairs of esophageal adenocarcinoma (EAC) cell lines and
corresponding 5-FU resistant variants were established. The expression levels
of miRNAs previously shown to be involved in the general regulation of stem
cell pathways were analyzed by qRT-PCR. The effects of selected miRNAs on
proliferation, apoptosis, and chemosensitivity were evaluated both in vitro and
in vivo. We identified a particular miRNA and analyzed its putative target
genes in 14 pairs of human EC tumor specimens with surrounding normal
tissue by qRT-PCR as well as Wnt pathway associated genes by immuno-
histochemistry in another 45 EAC tumor samples.
Results: MiR-221 was overexpressed in 5-FU resistant EC cell lines as well as
in human EAC tissue. DKK2 was identified as a target gene for miR-221.
Knockdown of miR-221 in 5-FU resistant cells resulted in reduced cell
proliferation, increased apoptosis, restored chemosensitivity, and led to inac-
tivation of the Wnt/b-catenin pathway mediated by alteration in DKK2 expres-
sion. Moreover, miR-221 reduction resulted in alteration of EMT-associated
genes such as E-cadherin and vimentin as well as significantly slower xenograft
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tumor growth in nude mice. RT profiler analysis identified a substantial
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804 | www.annalsofsurgery.comdysregulation of 4 Wnt/b-catenin signaling and chemoresistance target genes
as a result of miR-221 modulation: CDH1, CD44, MYC, and ABCG2.
Conclusion: MiR-221 controls 5-FU resistance of EC partly via modulation
of Wnt/b-catenin-EMT pathways by direct targeting of DKK2 expression.
MiR-221 may serve as a prognostic marker and therapeutic target for patients
with 5-FU resistant EAC.
Keywords: 5-FU resistance, epithelial-mesenchymal transition, esophageal
cancer, miR-221, Wnt/b-catenin signaling
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E sophageal cancer (EC) is the eighth most common cancer and thesixth most common cause of cancer death.1 The current clinical
treatment options for EC are surgery, chemotherapy, and radio-
therapy. The prognosis of patients receiving surgery alone is still
poor.2 Multimodal treatment improves the survival. Survival rates
following esophagectomy with added neoadjuvant therapy are
increasing to 30% to 45% for 5-year survival.3 However, the response
rate to chemotherapy, including 5-FU, is still lower than 50%.4
Chemoresistance is thus seen as a major obstacle in the effective
treatment of EC. The 2 main subtypes of the disease are esophageal
squamous-cell carcinoma (often abbreviated to ESCC), which is
more common in the developing world, and esophageal adenocarci-
noma (EAC) is more common in the European and north American
countries,5 highly associated with smoking tobacco, obesity, and acid
reflux.6
MicroRNAs (miRNAs) are small 19 to 22nt noncoding
single-strand RNAs that mediate gene expression by interacting
with the 30UTR regions of their target gene mRNA and blocking its
translation.7 MiRNAs have been shown to regulate diverse cellular
processes, including cell proliferation, stemness and differen-
tiation, apoptosis, as well as therapy resistance.8 Accumulating
evidence suggests that miRNAs are dysregulated in a variety of
cancers including EC. Cancer chemoresistance is a complicated
process manifested through multiple mechanisms, including DNA
damage repair, expression of ATP-binding cassette drug trans-
porters, and activation of PI3K/AKT and Wnt pathways.9–13 In
addition, micro-environmental stimuli such as tissue hypoxia or
signals that influence epithelial-mesenchymal transition can also
impact chemoresistance.9–13 Recent reports have described miR-
141, miR-200c, miR-148a, miR-296, and miR-27a as functionally
contributing to chemoresistance of EC.14–19 Overexpression of
miR-200c was shown to induce resistance in ECs through acti-
vation of the Akt signaling pathway.15 However, the molecular
mechanism underlying this observation remains unclear. In the
present study, we show that miR-221 expression is significantly
increased in 5-FU resistant EC cell lines and the underlying
molecular mechanism was further elucidated in a series of in vitroer Health, Inc. All rights reserved.
and in vivo experiments.
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Cell Culture and Establishment of Chemotherapy-
Resistant EC Cell Lines
The OE19 and OE33 human EC cell lines were obtained from
the Sigma Cell Line Bank (Sigma, 96071721 and 96070808). Two
additional human EC cell lines, PT1590 and LN1590, were provided
by the University Medical Center of Hamburg-Eppendorf. All cell
lines were maintained in culture as described previously.19 5-FU
resistant EC cell lines (OE19–5Fures, OE33–5Fures, PT-5Fures, and
LN-5Fures) were developed through a stepwise incremental treatment
with 5-FU as follows: the initial concentration of 5-FU used was set
at 5 mg/mL on the basis of IC50 values ranging between 3 and 6.5 mg/
mL for the original sensitive cell lines. After 24 hours, the cells were
passaged with 5-FU free medium. Upon reaching confluency, the
cells were treated with increasing levels of 5-FU (1.5- to 2-fold).
After 5 subsequent steps with increasing 5-FU concentration, the
resistant cell lines were eventually established.
Tissue Specimens
Tissue samples were obtained from patients with EAC
between 2005 and 2015 at the Department of Surgery, University
of Magdeburg, Germany (Ethic Committee approval 33/01, Univer-
sity of Magdeburg, Magdeburg, Germany). The description of these
specimens is detailed in supplementary table S1, http://link-
s.lww.com/SLA/B69.
MiRNA and Gene Expression Analysis
Total RNA from fresh-frozen esophageal tumor tissues or cell
lines was isolated using QIAzol lysis reagent (Qiagen, USA).
Expression of let-7b, let-7g, miR-21, miR-34a, miR-92, miR-
200c, and miR-221 was determined using miScript SYBR Green
PCR kits (Qiagen, USA). Expression of RNU6B (Qiagen, USA) was
used as endogenous control. miRNAs sequences are provided in the
supplementary table S2, http://links.lww.com/SLA/B69. For deter-
mining steady-state mRNA expression, total RNA was reverse tran-
scribed to cDNA and qRT-PCR was performed as described
previously.20 Primer sequences are provided in supplementary table
S3, http://links.lww.com/SLA/B69.
Transfection of miR-221 Mimics, miR-221 Inhibitor,
and CTNNB1 siRNA
To transiently modulate miR-221 expression, hsa-miR-221
mimics (Qiagen, Cat. no: MSY0000278, USA), hsa-miR-221 inhibi-
tor (Qiagen, Cat. no: MIN0000278, USA), or negative control siRNA
(Qiagen, Cat. no: 1022076, USA) were transfected into 5-FU sensi-
tive or resistant EC cells.20 To suppress CTNNB1, expression cells
were transfected with either CTNNB1 siRNA (GE Healthcare,
Cat.no: M-003482-00-0005) or negative control siRNA using Hiper-
Fect transfection reagent (Qiagen, Cat.no:301705, USA). Sequences
for the hsa-miR-221 mimics, hsa-miR-221 inhibitor, and CTNNB1
siRNA are provided in Table S4.
TOP Flash Luciferase Report Assay
To assess TCF-b-catenin mediated transcriptional activity,
hsa-miR-221 mimics/inhibitor or siR-CTNNB1 and/or the
8TOP-flash reporter gene construct were cotransfected into cells,
and TOP-flash luciferase reporter gene assays were performed using
a Luciferase Reporter Assay System (Promega, Madison, WI).21
Protein Analysis
Western blotting was performed as described previously.22 Copyright © 2016 Wolters Klu
Antibody information is provided in supplemental materials, http://
 2016 Wolters Kluwer Health, Inc. All rights reserved.links.lww.com/SLA/B69. The protein bands were visualized using a
Leica DFC450D fluorescence microscope (Leica, Wetzlar, Germany).
Cell Proliferation, Apoptosis, and Chemosensitivity
Regarding cell proliferation, EC cells were analyzed at 0,
24, 48, and 72 hours after transfection with hsa-miR-221 mimics
(miR-221), hsa-miR-221 inhibitor (anti221), or negative control
siRNA (siRCtrl) using the Cell Counting kit-8 (CCK-8) (Dojindo
Laboratories, Kumamoto, Japan). Annexin V–fluorescein isothio-
cyanate (FITC) and propidium iodide (PI) staining (Miltenyi
Biotec, Germany) were applied to determine the percentage
of transfected cells undergoing apoptotic or necrotic cell death
after 24 hours. To assess cytotoxicity of 5-FU, all transfected
cells were analyzed at 48 hours following 2.5 or 20 mg/mL
5-FU treatment.
Esophageal Adenocarcinoma Xenograft Mouse
Model
To determine tumor growth in vivo, EC cells transfected with
miR-221, anti221, or siRCtrl were implanted into the flanks of 6 to 8-
week-old male Balb/c nu-nu mice (Charles River Deutschland,
Sulzfeld, Germany). Tumor size was measured in specified time
intervals. Upon sacrifice of the animals, tumor volume was calcu-
lated and analyzed. All protocols were approved by the regional
commission for animal experiments in the state of Sachsen-Anhalt of
Germany (no.42502-2-1266 uniMD).
Histology and Immunostaining
For immunohistochemical staining samples from the in vivo
animal experiments, patient-derived esophageal tumor or adjacent
normal tissues were fixed, embedded and sectioned at 3 mm thick-
ness. These sections were then stained with anti-Ki67 (1 : 100,
Abcam, UK), anti-b-catenin (1 : 500, BD Bioscience, Cat.no:
610154, USA), and anti-DKK2 (1 : 200, Abcam, UK).
20 Frozen
tumor tissues embedded in O.C.T at 208C and sectioned to
3 mm thickness were used for immunofluorescent staining with
anti-CD31 (1 : 50, Abcam, UK).
RT2 Profiler PCR Array System
The expression of selected Wnt/b-catenin-EMT related genes
was examined using the Custom Human RT2 Profiler TM PCR array
(RT2 Profiler TM PCR Array: CAPH12950), which includes targets
of the Wnt/b-catenin signaling pathway as well as genes associated
with the general process of EMT. Total RNA was isolated from
5 x 105 OE33 and OE33-5Fures cells with or without hsa-miR-221
mimics, inhibitor, or siR-CTNNB1 using the miRNeasy kit. PCR was
performed with the RT2 profiler PCR array system and analyzed
using an ABI 7000 PCR machine. The expression levels of different
mRNAs were normalized using a series of housekeeping genes:
ACTB, B2M, GAPDH, HPRT1, and RPLP0. The fold change of gene
expression from the different treatment as compared with control
groups was calculated as 2(DDCT).
Statistical Analysis
All data are expressed as meanSD. The correlation of b-
catenin or DKK2 and each clinical pathologic variable was com-
paratively analyzed by x2 test and the Fisher exact test. A P value of
less than 0.05 indicated the presence of statistically significant
difference between groups. All statistical analyses were carried
out with Graphpad Prism 6. For RT2 profiler data analysis, we
applied a web-based service of Qiagen data analysis center. Genes
were called ‘‘differentially expressed’’ if the corrected P value waswer Health, Inc. All rights reserved.
less than 0.05.
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FIGURE 1. miRNA expression in esoph-
ageal cancer cell lines and patient tissues.
A, Relative expression of selected miRNAs
assessed in 4 pairs of 5-FU sensitive and
resistant esophageal cancer cells by
qPCR. B, miR-221 expression in 4 esoph-
ageal adenocarcinoma cell lines. C, miR-
221 expression in 14 sets of correspond-
ing tumor and nontumor specimens
derived from esophageal cancer patients.
NT indicates nontumor; TU, tumor.
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miR-221 is Upregulated in 5-FU Resistant EC Cells
Lines and Tumor Tissues
The biology underlying stemness has been linked to the
biology of chemoresistance.23–25 A series of miRNAs have been
previously implicated in the regulation of ‘‘stem cell’’ function.26,27
To study the role of miRNAs in the context of chemotherapy
resistance in EC, we established a series of 5-FU resistant EC cell
lines (OE19-5Fures, OE33-5Fures, LN-5Fures, and PT-5Fures) (Fig.
S1, http://links.lww.com/SLA/B69) and then analyzed them for their
differential expression of miRNAs by RT-qPCR. In a panel of 5-FU
resistant EAC cells (OE19, OE33, PT1590, and LN1590), miR-221
was overexpressed in all resistant variants (Fig. 1A). The highest
expression of miR-221 was found in the OE33 cell line (Fig. 1B).
However, we did not show all miRNA transfection data in the other 3
cell lines; OE19-5FUres did not display an ideal growth under
transfection. Therefore, OE33 and OE33-5Fures cells were selected
for the subsequent functional studies. MiR-221 was further validated
in EC patient’s samples. MiR-221 was significantly higher expressed
in tumor than in adjacent normal tissue from 14 EC patients (Fig. 1C,
P ¼ 0.0107).
Inhibition of miR-221 in EC Cells Decreases Cell
Proliferation, Induces Apoptotic Cell Death, and
Restores 5-FU Sensitivity
To investigate the role of miR-221 on proliferation, cell
death, and chemosensitivity for EC, OE33-5Fures cells were tran-
siently transfected with has-miR-221 mimics (miR-221), miR-221
inhibitor (anti-221), or negative control siRNA (siRCtrl) (Fig. 2A).
Transfection of miR-221 inhibitor (anti-221) significantly reduced
cell viability (Fig. 2B) and increased the proportion of apoptotic
cells (Figs. 2C, D) as compared with negative control siRNA
in OE33-5Fures cells (45.63 2.76% vs 5.44 1.26% at 24 hours, Copyright © 2016 Wolters Kluw
P < 0.001).
806 | www.annalsofsurgery.comTransient knockdown of miR-221 expression was found to
restore sensitivity of OE33-5Fures cells to 5-FU leading to an
increasing percentage of dead OE33-5Fures cells after re-introduction
of 2.5 and 20 mg/mL 5-FU treatment (4.7-fold and 1.5-fold, Fig. 2E).
In addition, the protein expression of thymidylate synthase
(TS), a known 5-FU target and resistance marker, was reduced by
transient miR-221 knockdown in OE33-5Fures as evidenced by
western blotting (Fig. 2F).
Knockdown of miR-221 Inhibits Tumor Growth In
Vivo
BALB/c nu-nu male mice were obtained from Charles River
Deutschland (Sulzfeld, Germany) at 6 to 8 weeks of age and housed in
the animal facility of the University Medical Center Magdeburg.
Thirty mice were randomized into 6 groups (5 mice per group). EC
tumor xenografts were established by subcutaneous injection of 1 x 106
of OE33 or OE33-5Fures following transfection with has-miR-221
mimics, miR-221 inhibitor, or negative control siRNA in the same
position on the flanks of nude mice. Sixty-six days after injection,
all mice were sacrificed and the harvested tumors were analyzed.
Knockdown of miR-221 in OE33-5Fures cells led to a significantly
slower tumor growth in vivo than controls (anti-221 vs Ctrl or siRCtrl,
P< 0.001, Fig. 3C). Immunohistochemical analysis revealed that Ki67
was significantly weaker expressed in the anti-221 transfected OE33-
5Fures cells than the controls (anti-221 vs Ctrl or siRCtrl, P< 0.0001)
(Fig. 3E). CD31 was performed to analyze effects on tumor angio-
genesis. OE33-5Fures control tumors revealed a high number of CD31-
positive cells, which was substantially reduced in anti-221 transfected
OE33-5Fures tumors (P < 0.05) (Fig. 3F).
DKK2 is a Direct Target of miR-221 and miR-221
Induced Chemoresistance is Mediated Through the
Wnt/b-catenin Signaling
To search for target genes of miR-221, we used 4 miRNAer Health, Inc. All rights reserved.
target prediction tools: TargetScan, PITA, miRTarBase, and miRanda
 2016 Wolters Kluwer Health, Inc. All rights reserved.
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FIGURE 2. Functional analysis of miR-221 in 5-FU resistant EC cells. A, Efficacy of has-miR-221 mimics, has-miR-221 inhibitor in EC
cells. Transfection with miR-221 mimics increases miR-221 expression in 5-FU sensitive EC cell (OE33), while transfection with miR-
221 inhibitor decreases miR-221 expression in 5-FU resistant EC cell (OE33-5Fures). B, Cells were transfected and their viability
determined by CCK-8 assay at 0, 24, 48, and 72 hours. The viability of control cells, cells transfected with miR-221 mimics (miR-
221), inhibitor (anti221), and negative control siRNA (siRCtrl) was detected. Inhibition of miR-221 expression led to reduction of cell
proliferation. P< 0.05, yP< 0.01, 2-way ANOVA. C, Analysis of cell apoptosis of 5-FU sensitive and resistant OE33 cells at 24 hours
after transfection. Overexpression of miR-221 had no impact on the cell apoptosis of 5-FU sensitive EC cells, while inhibition of miR-
221 significantly promoted the cell apoptosis of 5-FU resistant EC cells. D, Annexin V-positive cells were quantified by flow
cytometry. Data are presented as mean SD of 3 independent experiments. E, Cell response to 5-FU (2.5 and 20 mg/mL) after
transfection. With 20 mg/mL of 5-FU, treatment-naive OE33 cells showed a 50.3%4.1% reduction of viable cells of as compared
with 36.9%4.1% in miR-221 mimic transfected cells (P < 0.05), while in OE33-5FUres cells, reduction of viable cells was
significantly increased from 23.0%4.6% to 37.0%8.7% (P < 0.01). F, Protein expression of 5-FU resistant marker TS in OE33
and OE33- 5Fures cells. Transfection with miR-221 mimics slightly increased TS protein expression, while transfection with miR-221
inhibitor significantly decreased TS protein level.
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FIGURE 3. Analysis of in vivo EC tumorigenesis in a xenograft nude mouse model. A–C, Increased expression of miR-221 led to
enhanced OE33 tumor growth in a xenograft nude mouse model, knockdown of miR-221 expression inhibited OE33-5FUres tumor
growth. P < 0.05, yP < 0.01, 2-way ANOVA. D–F, Immunohistochemical analysis of cell proliferation and immunofluorescence
staining of angiogenesis. In tumors with miR-221 overexpression, Ki67 expression was significantly higher than in control groups
(P< 0.0001). In tumors with low levels of miR-221 of OE33-5FUres after antagomir therapy, the expression of Ki67 was significantly
reduced (P < 0.0001). CD31 expression was dramatically increased in miR-221 transfected OE33 (P < 0.01) and decreased in
OE33-5FUres tumor with anti-miR-221 therapy (P < 0.05).
Wang et al Annals of Surgery  Volume 264, Number 5, November 2016
808 | www.annalsofsurgery.com  2016 Wolters Kluwer Health, Inc. All rights reserved.
 Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved.
FIGURE 4. Identification of miR-221 target genes and its regulation of the Wnt/b-catenin signaling pathway (A) Prediction of miR-
221 target genes. One hundred twenty target genes that have miR-221 seed sites are predicted via 4 different miRNA target
prediction tools (TargetScan, PITA, miRTarBase, and miRanda). B–D, DKK2 expression in esophageal tumor tissue and esophageal
cancer cells. DKK2 was substantially lower expressed in esophageal tumors than in adjacent nontumor tissues. Furthermore, DKK2
was downregulated in 5-FU resistant EC cells compared with the respective sensitive cells. Overexpression of miR-221 suppressed
mRNA (detected by qRT-PCR) and protein (detected by western blot) expression of DKK2 while downregulation of miR-221
increased both DKK2 mRNA and protein expression. E, Distribution of b-catenin in esophageal tumor tissues. Nuclear localization of
b-catenin in 5-FU treated esophageal tumors. 5-FU indicates 5-fluoruracil; NCT, no chemotherapy.
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Wang et al Annals of Surgery  Volume 264, Number 5, November 2016(Fig. 4A). Among a large number of potential targets based on
bioinformatic investigations, we identified DKK2 for further func-
tional analysis. A potential targeting of the 30UTR of the human
DKK2 gene by miR-221 was predicted by the TargetScan and
RNAhybrid software and further supported by the high level of
evolutionary conservation of the seed sequence between species
(data were not shown).
qPCR analysis showed that DKK2 mRNA levels were
reduced in tumor samples as compared with nontumor tissue
samples and in 5-FU resistant as compared with 5-FU sensitive
EC cells. Thus, expression of DKK2 is inversely correlated to
expression of miR-221 (Figs. 1C, 4B). However, due to the sample
size, the statistics of correlation analysis between miR-221 and
DKK2 mRNA expression is not significant (P ¼ 0.216, R ¼ 0.339;
nonparametric spearman correlation). In addition, miR-221 knock-
down resulted in a significant increase in DKK2 mRNA and protein
expression (Figs. 4C, D).
To verify that DKK2 is a direct target of miR-221, luciferase
reporter vectors were then applied. Overexpression of miR-221
dramatically decreased the luciferase reporter activity when the
wild-type DKK2 3
0UTR was used, but did not influence reporter
expression when the DKK2 mutant control construct containing
mutant seed sequences was used (data were not shown).
To investigate a potential association between miR-221
expression, chemoresistance, and activation of the Wnt/b-catenin
signaling pathway, b-catenin distribution and DKK2 expression were
detected in tumor samples. We found no significant difference in
DKK2 expression in Barrett’s mucosa (9/33, 27.3%) or tumor tissues
(7/33, 21.2%) before chemotherapy. However, samples from esoph-
ageal tumor patients with prolonged exposure to chemotherapy
showed a substantial decrease in DKK2 expression (1/12, 8.3%)
as compared with the corresponding expression level seen in adjacent
Barrett’s mucosa (3/12, 25.0%).
Tumor samples following chemotherapy also demonstrated
evidence of enhanced canonical Wnt signaling. Although inactivated
b-catenin was mainly localized to the cell membrane and cytoplasm
in Barrett’s mucosa (31/33, 93.9%) and EAC specimens without
chemotherapy treatment (27/33, 81.8%), an accumulation of nuclear
b-catenin was found in EAC after long-term exposure to 5-FU based
chemotherapy (5/12, 41.7%) (Fig. 4E). Among all available clinical
and pathological parameters, only DKK2 expression was found
to significantly correlate with the stage of tumor differentiation
(P ¼ 0.024, Table 1).
To validate the functional role of miR-221 regulating
b-catenin activation, OE33-5Fures cells were transfected with Copyright © 2016 Wolters Kluw
has-miR-221 mimics, inhibitor, siR-CTNNB1/siR-b-catenin, or









Age (meanSD), y 67.6 11.4 70 10.2
Differentiation
Well differentiated 7 (20.6%) 1 (9.1%)
Moderately differentiated 14 (41.2%) 6 (54.5%)
Poorly differentiated 13 (38.2%) 4 (36.4%)
Stage (IþII/IIIþIV) 22/12 5/6
pT (T1/T2/T3/T4) 16/4/14/0 7/2/2/0
pN (N0/N1/N2/N3) 20/10/0/4 8/2/1/0
Chemotherapy (5-Fu based)
Yes 7 (20.6%) 5 (45.5%)
No 27 (79.4%) 6 (54.5%)
810 | www.annalsofsurgery.comnegative control siRNA (Fig. 2A, S2B and C, http://links.
lww.com/SLA/B69). TOP Flash luciferase reporter analysis showed
decreased luciferase activity following transfection with miR-221
inhibitors equivalent to siR-CTNNB1/siR-b-catenin (P < 0.01,
Fig. S3B, http://links.lww.com/SLA/B69). These results suggest that
miR-221 influences chemoresistance at least in part through
activation of the Wnt/b-catenin pathway via direct control of
DKK2 expression.
miR-221 Mediates EMT Through Activating
Wnt/b-catenin Signaling
EMT is associated with chemoresistance in various cancers.
We observed a morphological change toward a mesenchymal cell
phenotype in 5-FU resistant EC cells (Fig. 5A). Western blot analysis
showed that the epithelial cell marker E-cadherin was expressed at a
lower level, whereas the mesenchymal cell marker Vimentin was
expressed at a higher level in OE33-5Fures cells than the respective
sensitive EC cells. These results suggest that the process of EMT is
associated with the development of 5-FU resistance in EC cells.
Interestingly, a knockdown of miR-221 expression in OE33-5Fures
resulted in a significant increase in E-cadherin and a decrease in
Vimentin protein expression (Fig. 5B).
To validate downstream effects of miR-221 expression on
regulation of Wnt/b-catenin signaling and EMT, we identified 30 b-
catenin target genes related to EMT by PCR array (Fig. 5C, Table S6,
http://links.lww.com/SLA/B69). Four genes MYC, CD44, ABCG2,
and CDH1 were significantly dysregulated between OE33 and
OE33-5Fures, following induction or inhibition of miR-221 (Fig. 5D).
DISCUSSION
MiR-221 is located on chromosome X and is overexpressed in
osteosarcoma,28 colorectal,29 ovarian,30 breast,31 and pancreatic
cancer.20 One current study showed that miR-21, miR-143, miR-
203, miR-205, and miR-221 were overexpressed in squamous-cell
carcinoma cancer tissues compared with normal esophageal tis-
sues.32 In colorectal cancer, miR-221 promotes cell proliferation.29
In addition, miR-221 plays a role in mediating radio-chemoresist-
ance of various cancers by targeting various signal transduction
pathways.28,31,33,34 Targeting of the PI3K/Akt signaling axis by
miR-221 can induce cell proliferation and BCNU resistance in
human glioblastoma.35 Downregulation of miR-221 also alters radi-
ation sensitivity in these cells by targeting the PTEN pathway.36
Overexpression of miR-221 is associated with tamoxifen resistance
in breast cancer through its negative regulation of estrogen receptor
31er Health, Inc. All rights reserved.
alpha. Furthermore, miR-221 has been shown to confer breast






n ¼ 8 P
0.536 67.0 10.4 72.8 13.1 0.179
0.619 0.024
8 (21.6%) 0 (0%)
13 (35.1%) 7 (87.5%)
16 (43.2%) 1 (12.5%)
0.257 23/14 4/4 0.524
0.379 19/6/12/0 5/0/3/0 0.472
0.169 22/10/1/4 6/2/0/0 0.718
0.136 0.419
11 (29.7%) 1 (12.5%)
26 (70.3%) 7 (87.5%)
 2016 Wolters Kluwer Health, Inc. All rights reserved.
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FIGURE 5. Effects of miR-221 on the interaction of WNT/b-catenin signaling and EMT in EC cells. A, Morphological comparison
of 5-FU sensitive and resistant EC cells: spindle-like phenotype in 5-FU resistant OE19 and OE33 cells. B, EMT-related markers
E-cadherin and Vimentin are regulated by miR-221 in OE33 and OE33-5Fures cells. C, D, EMT-related Wnt/b-catenin target genes
are expressed differently in OE33 and OE33-5Fures cells following transfection with miR-221 mimics, inhibitor or siR-CTNNB1.
Four genes CDH1, MYC, CD44, and ABCG2 were regulated by both miR-221 and b-catenin. E, The above results suggest that miR-
221 acts as a driver of 5-FU resistance in EC. A potential signaling axis between miR-221-DKK2-WNT/b-catenin-EMT was identified
in EC. MiR-221 activates the WNT/b-catenin pathway by direct targeting of DKK2 (an antagonist of the WNT/b-catenin pathway),
leading to enhanced cell proliferation. Activation of the WNT/b-catenin pathway leads to accumulation of TS with increase of
chemoresistance and epithelial-mesenchymal transition by regulating its downstream targets (c-myc, E-cadherin, CD44, and
ABCG2).
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pathways.34 In a previous study, we showed that combined suppres-
sion of miR-21 and miR-221 sensitized pancreatic cancer cells to
treatment with either gemcitabine or 5-FU. Accordingly, our finding
that miR-221 is overexpressed in EC cells prompted us to speculate
an association between miR-221 and chemotherapy resistance in
EC.20 In general, chemotherapy regimens for EC are 5-FU based.
Hummel et al37 used an in vitro model of acquired chemotherapy
resistance in esophageal adeno- and squamous cell carcinoma cells
showing miRNA expression profiles for cisplatin or 5-FU resistant
variants versus chemotherapy-sensitive controls and found miR-27b-
3p, miR-193b-3p, miR-192-5p, miR-378 a-3p, miR-125a-5p, and
miR-18a-3p dysregulated.
In this study, we show that expression of miR-221 is associated
with 5-FU resistance and EC tumor growth. Furthermore, we dem-
onstrate that increased expression of miR-221 correlates with acti-
vation of Wnt/b-catenin signaling and EMT in EC cells. The Wnt/b-
catenin signaling pathway is indeed linked to cancer progression and
chemoresistance in various tumors via EMT.38–40 An antagonist of the
Wnt/b-catenin pathway is DKK2,
41 a member of the Dickkopf family,
which is activated by treatment with 5-FU.42,43 We thus speculated that
miR-221 might account for 5-FU resistance in EC by modulation of
DKK2 expression. To address this, we examined the expression of
DKK2 together with the distribution of b-catenin in EAC tumor
specimens. Our immunohistochemistry analysis demonstrated no
significant difference in DKK2 expression in Barrett’s mucosa or
EC tumor tissue before chemotherapy. We speculate that the missing
statistical significance of the correlation analysis between DKK2, b-
catenin and chemotherapy might be a consequence of limited sample
size. Interestingly, esophageal tumor specimens following prolonged
exposure to chemotherapy showed a substantial decrease in DKK2
expression together with an accumulation of nuclear b-catenin
(Fig. 4E), while inactivated b-catenin was mainly localized to the
cell membrane and cytoplasm in Barrett’s mucosa and EAC specimens
without prior chemotherapy treatment. These results suggest that miR-
221 influence chemoresistance at least in part through activation of the
Wnt/b-catenin pathway via regulation of DKK2 expression.
In correlation to changes of miR-221 expression, we further
identified significant alterations in expression levels of b-catenin/
Wnt- and EMT-associated genes such as MYC, CD44, CDH1, and
ABCG2. We therefore propose that increased expression of miR-221
leads to reduced expression of DKK2, further releasing an activation
of the Wnt/b-catenin pathway resulting in nuclear translocation of b-
catenin with corresponding expression of Wnt target genes.
Accordingly, our results suggest that miR-221 functions as an
oncomiR in EAC. Moreover, the present study is the first to connect
Wnt/b-catenin signaling and EMT-related gene expression in associ-
ation to 5-FU resistance of EC. The potential mechanism for this
general phenomenon is summarized in Fig. 5E.
Chemoresistance is a major issue for effective treatment of
EC. On the basis of our results, increased miR-221 could either act as
a surrogate marker to predict chemotherapy resistance or as a
potential therapeutic target against chemotherapy resistance in EAC.
The results show a decrease in the expression of DKK2 in
esophageal tumor tissues, and nuclear accumulation of b-catenin in
5-FU resistant EC cells, and in tumor samples linked to a poor
response to 5-FU therapy. The data suggest a tendency toward
activation of the Wnt/b-catenin pathway in EAC that is associated
with long time exposure to anticancer drugs especially 5-FU. How-
ever, due to the limitation of acquiring more EAC tissues from either
local or independent clinical centers, we expected this finding could
be further confirmed in other studies.
We further validated significant changes in the expression Copyright © 2016 Wolters Kluw
levels of b-catenin/Wnt- and chemotherapy-associated genes MYC,
812 | www.annalsofsurgery.comCD44, CDH1, and ABCG2 in response to changes in miR-221
expression. On the basis of our results, we propose that increased
expression of miR-221 leads to reduced expression of DKK2, further
releasing a DKK2-mediated blockade of the Wnt/b-catenin signaling
pathway. Increased activation of this pathway results in disruption of
the Axin/APC/GSK3 degradation complex leading to stabilization of
b-catenin. b-catenin then translocates to the nucleus wherein it helps
control expression of Wnt targets.
Our results suggest that miR-221 functions as an oncomiR in
EAC by direct targeting of DKK2, as evidenced by the associated
effects observed on the Wnt/b-catenin signaling pathway. Processes
linked to EMT resulted from the continuous 5-FU treatment of EAC
cell lines. EMT has been previously associated with 5-FU resist-
ance44–46 and miR-221 in pancreatic cancer cells.47
The present study is the first to connect Wnt/b-catenin pathway
and the process of EMT in 5-FU resistance of EAC. The potential
mechanism for this general phenomenon is summarized in Fig. 5E.
Chemoresistance is a major issue in the effective treatment of
EAC. Thus, detecting rational biomarkers to predict chemotherapy
sensitivity and screening for targets to overcome resistance are
significant for cancer therapy. On the basis of our results, increased
miR-221 expression is associated with chemotherapy resistance and
poor prognosis. MiR-221 may thus act as a surrogate marker to
predict chemoresistance in EAC.
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DISCUSSANTS
L. Bonavina (Milano, Italy):
Tumor heterogeneity and chemoresistance remain indeed a
main issue for an effective neo-adjuvant therapy in esophageal
adenocarcinoma. 5-FU has been a mainstay of treatment for a long
time, but most clinical studies have focused on speed of drug delivery
(whether bolus or continuous) and on the enzimatic defects associ-
ated with 5-FU toxicity rather than on chemoresistance.
You have described a large set of experiments showing that
miR-221 positive tumor cells have more malignant potential and are
more resistant to 5-FU than naive tumor cells. You have also shown
that miR-221 may serve as a prognostic marker and as a therapeutic
target for patients with 5-FU resistant esophageal adenocarcinoma.
To be considered an efficient prognostic marker, miR-221
needs further validation in clinical trials. In addition, the possibility
to sample blood or other body fluids should be investigated to assess
specificity and sensitivity in esophageal adenocarcinoma.
My questions for you are the following: First, is there any
possible relationship between speed of 5-FU delivery and induction
of chemoresistance? Second, is there any association between the
risk of 5-FU toxicity and 5-FU chemoresistance? Third, would you
speculate that knockdown of miR-221 to restore chemosensitivity
to 5-FU may be the winning strategy in the future or rather that it
may be more convenient to focus on the more innovative
targeted drugs?
Response From C. Bruns (Cologne, Germany):
With respect to the possible relationship of the speed of 5-FU
delivery or continuous versus bolus 5-FU application, all analyzed
specimen derived from patients who received continuous 5-FU
injection within their chemotherapy protocol. However, I think that
indeed long-term, continuous exposure to 5-FU—here in the exper-
imental setting even with increasing doses—induces resistance
mechanisms and select for cell populations that are highly resistant.
Transferred to clinical situations, protocols with short-term exposure
to chemotherapy should rather be conducted.
With respect to second question, we did not find any associ-
ation between 5-FU toxicity and 5-FU resistance. 5-FU toxicity is
based on a DPD mutation and we have not investigated the cell lines
regarding their DPD mutational status.
With respect to the last question, we indeed speculatewer Health, Inc. All rights reserved.
that possible new techniques to target resistant esophageal
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for resistance. Another option would be to target downstream
molecular markers or pathways associated with specific miR-RNAs.
As miR-221 is activating the wnt-pathway, it would be interesting to
think of wnt-inhibitors as therapeutic targets of resistant esophageal
adenocarcinoma. A well-known wnt-inhibitor is aspirin, which is
already been known to interfere in GI malignancies with the
adenoma-carcinoma sequence.
J.V. Reynolds (Dublin, Ireland):
miR-221, in addition to being an oncogene, is also a known
tumor-suppressor gene and low expression levels or downregulation
are implicated, for example, in the development of oropharyngeal
SCCs. It also downregulates the c-kit receptor, so it is implicated in
the development of hemopoietic malignancies. Did you notice when
you knocked down miR-221 expression that it induced development
of SCCs in the oropharynx or did you check in your mice if there Copyright © 2016 Wolters Kluw
814 | www.annalsofsurgery.comFinally, do you have plans to measure miR-221 in pre-
and post-neoadjuvant chemoradiotherapy esophageal biopsies
to see if expression levels change in response to effective
treatment?
Response From C. Bruns (Cologne, Germany):
No, we did not check our animals for development of
oropharyngeal SCCs.
However, we analyzed commercially available esophageal
SCC cell lines and found the expression of miR-RNA 221 in these
esophageal SCC cell lines not that impressive.
With respect to your second question, we have not
yet analyzed pre- and post-neoadjuvant chemoradiotherapy
esophageal biopsies. We only analyzed full histology samples
after esophageal tumor resection. In the future, this would
of course be the correct way to identify miR-RNA 221 expression
in tumor biopsies to individualize chemotherapy for each
patient.were any erthyropoietic maligancies as a consequence of that?er Health, Inc. All rights reserved.
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